



(51) International Patent Classification:

C07D 211/16 (2006.01) **A61K 31/435** (2006.01)
C07D 211/26 (2006.01)

(21) International Application Number:

PCT/KR2011/002759

(22) International Filing Date:

18 April 2011 (18.04.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2010-0038039 23 April 2010 (23.04.2010) KR

(71) **Applicant** (for all designated States except US): **DONG-A PHARM.CO., LTD.** [KR/KR]; 252, Yongdu-dong, Dongdaemun-gu, Seoul 130-823 (KR).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **KIM, Soon-Hoe** [KR/KR]; 316-702, Cheongmyeong Maeul Dongsin Apt., 956-2, Yeongtong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-809 (KR). **IM, Weon-Bin** [KR/KR]; 105-702, Ggotme Maeul Hyundai I-Park 2-Cha Apt., Jukjeon 1-dong, Suji-gu, Yongin-si, Gyeonggi-do 448-161 (KR). **CHOI, Sung-Hak** [KR/KR]; 524-203, Yangji Maeul Hanyang Apt., Sunae-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-922 (KR). **CHOI, Sun-Ho** [KR/KR]; 102-401, Seocho Kukdong Starclass 1 Apt., 1616-10, Seocho-dong, Seocho-gu, Seoul 137-877 (KR). **SOHN, Ju-Hee** [KR/KR]; 903, Sambu Renaissance Parkville Apt., 137-4, Garibong-dong, Guro-gu, Seoul 152-801 (KR). **SUNG, Hyun-Jung** [KR/KR]; 136-2003, Hanil Town Apt., Jowon-dong, Jangam-gu, Suwon-si, Gyeonggi-do 440-709 (KR). **KIM, Mi-Yeon** [KR/KR]; 202, 478-3, Sanggal-dong, Giheung-gu, Yongin-si,

Gyeonggi-do 446-905 (KR). **CHO, Kang-Hun** [KR/KR]; 707-1502, Sangnok Apt., 1060, Pungdeokcheon 2-dong, Suji-gu, Yongin-si, Gyeonggi-do 448-990 (KR). **SOHN, Tae-Kyoung** [KR/KR]; 114-902, Lotte Sunkyoung Apt., Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-500 (KR).

(74) **Agent:** **AHN, So-Young**; Dr. Ahn International Patent Law Office, 10th Fl., Shinseung Bldg., 1676-1, Seocho-dong, Seocho-gu, l, Seoul 137-881 (KR).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) **Title:** NOVEL BENZAMIDE DERIVATIVES

(57) **Abstract:** The present invention provides a novel benzamide derivative or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a 5-HT₄ receptor agonist containing the same as an active ingredient. Benzamide derivatives of the present invention have a superior affinity for 5-HT₄ receptors, a capability to reduce a gastric emptying time and a low toxicity, and consequently are therapeutically effective for the treatment of a variety of diseases associated with 5-HT₄ receptors.



WO 2011/132901 A2